1179343-95-3

Upstream product

• 931405-70-8 5-(azidomethyl)-1,6-diethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine 
• 932113-90-1 5-(chloromethyl)-1,6-diethyl-4-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridine-4-amine 
• 931405-72-0 5-(aminomethyl)-1,6-diethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine 
• 1179343-96-4 6-chloro-N-({3'-[((3S)-4-{[(1,1-dimethylethyl)-oxy]carbonyl}-3-methyl-1-piperazinyl)methyl]-6-fluoro-3-biphenylyl}methyl)-2-pyridinecarboxamide 
• 931405-67-3 [1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methanol 
• 4684-94-0 6-chloropicolinic acid 
• 865314-22-3 1,1-dimethylethyl (2S)-4-{[5'-(aminomethyl)-2'-fluoro-3-biphenylyl]methyl}-2-methyl-1-piperazinecarboxylate 
• 865713-74-2 ethyl 6-ethyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 865713-68-4 ethyl-4-chloro-6-ethyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 865713-63-9 diethyl 2-(1-chloropropylidene)malonate 
• 21633-77-2 diethyl 2-propionylmalonate 

Relevant academic research and scientific papers

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.